Physician profile
Samuel Abbas
NPI 1497105373
$9,281.57
in general payments reported to CMS, 2019-2025
41 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $1,000 · 2021: $1,811 · 2022: $2,606 · 2023: $2,032 · 2024: $1,220 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.31 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,172.80 | 2022 | |
| Novo Nordisk INC | $1,051.84 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $963.33 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $899.07 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $593.54 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $581.31 | 2019-2025 | |
| Amgen INC. | $579.61 | 2019-2025 | Prolia, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.30 | 2019-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $285.36 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.91 | 2019-2024 | Trintellix |
| Esperion Therapeutics, INC. | $217.15 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $206.76 | 2019-2023 | |
| Amarin Pharma, INC. | $204.37 | 2020-2022 | |
| Abbott Laboratories | $197.73 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $190.20 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.